Publicación: Eficacia de la Denervación simpática renal como ultimo escalafón terapéutico en hipertensión refractaria, revisión de la literatura.
dc.contributor.author | DULCEY SARMIENTO, LUIS ANDRES | spa |
dc.contributor.author | Castillo Blanco, Jhon Fredy | spa |
dc.contributor.author | Theran Leon, Juan Sebastian | spa |
dc.contributor.author | Caltagirone Miceli, Raimondo | spa |
dc.date.accessioned | 2025-07-21T07:12:32Z | |
dc.date.accessioned | 2025-08-05T14:25:29Z | |
dc.date.available | 2025-07-21T07:12:32Z | |
dc.date.available | 2025-08-05T14:25:29Z | |
dc.date.issued | 2025-07-21 | |
dc.description.abstract | Antecedentes: La hipertensión arterial acarrea una elevadísima carga de morbimortalidad por sus efectos deletéreos, pese al arsenal terapéutico tan amplio en algunos pacientes es refractaria. Estimaciones anteriores han colocado la carga global de enfermedad en adultos entre 30 y 32%, con la región de Asia Oriental y el Pacífico teniendo la mayor carga absoluta con poco más de 439 millones afectados. Además de las repercusiones en la salud, la hipertensión también conlleva costos económicos significativos. Metodología: Revisión amplia de la literatura sobre las actualizaciones en el área correspondiente al manejo de la hipertensión arterial refractaria y la utilidad de la terapia de denervación renal. Conclusiones: A pesar del tratamiento farmacológico bien establecido, la hipertensión sigue contribuyendo en gran medida a las muertes por enfermedades no transmisibles. Dada la bien conocida asociación de la hipertensión con enfermedades cardiovasculares adversas, la importancia del control de la presión arterial nunca ha sido más crucial. Tradicionalmente, el manejo farmacológico ha sido el pilar de la atención, sin embargo, con una carga de enfermedad cada vez mayor, ahora se están considerando enfoques alternativos e innovadores. Los sistemas de ablación basados en catéter mínimamente invasivos, dirigidos a los nervios simpáticos renales, se han propuesto como una forma más permanente de controlar la presión arterial. | spa |
dc.description.abstract | Background: Hypertension carries an extremely high burden of morbidity and mortality due to its deleterious effects, despite such a broad therapeutic arsenal in some patients it is refractory. Previous estimates have placed the global burden of disease in adults at between 30 and 32%, with the East Asia and Pacific region having the highest absolute burden with just over 439 million affected. In addition to the health repercussions, hypertension also carries significant economic costs. Methodology: Extensive review of the literature on updates in the area corresponding to the management of refractory arterial hypertension and the usefulness of renal denervation therapy. Conclusions: Despite well-established pharmacological treatment, hypertension continues to be a major contributor to deaths from noncommunicable diseases. Given the well-known association of hypertension with adverse cardiovascular disease, the importance of blood pressure control has never been more crucial. Traditionally, pharmacological management has been the mainstay of care, however, with an increasing burden of disease, alternative and innovative approaches are now being considered. Minimally invasive catheter-based ablation systems, targeting the renal sympathetic nerves, have been proposed as a more permanent way to control blood pressure. | eng |
dc.format.mimetype | application/pdf | spa |
dc.identifier.doi | 10.26752/cuarzo.v30.n1.640 | |
dc.identifier.eissn | 2500-7181 | |
dc.identifier.issn | 0121-2133 | |
dc.identifier.uri | https://repositorio.juanncorpas.edu.co/handle/001/440 | |
dc.identifier.url | https://doi.org/10.26752/cuarzo.v30.n1.640 | |
dc.language.iso | spa | spa |
dc.publisher | Fundación Universitaria Juan N. Corpas | spa |
dc.relation.bitstream | https://revistas.juanncorpas.edu.co/index.php/cuarzo/article/download/640/555 | |
dc.relation.citationendpage | 31 | |
dc.relation.citationissue | 1 | spa |
dc.relation.citationstartpage | 26 | |
dc.relation.citationvolume | 30 | spa |
dc.relation.ispartofjournal | Revista Cuarzo | spa |
dc.relation.references | Forouzanfar MH, Alexander L, Anderson HR, Bachman VF, Biryukov S, Brauer M, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study2013. Lancet. 2015;386(10010): 2287–323. | spa |
dc.relation.references | Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 Countries. Circulation. 2016;134(6):441–50. | spa |
dc.relation.references | Hird T, Zomer E, Owen A, Magliano D, Liew D, Ademi Z. Productivity burden of hypertension in Australia. Hypertension. 2019;73(4):777–84. | spa |
dc.relation.references | Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–67. | spa |
dc.relation.references | SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16. | spa |
dc.relation.references | Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–52. | spa |
dc.relation.references | Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635–42. | spa |
dc.relation.references | Yang Q, Chang A, Ritchey MD, Loustalot F. Antihypertensive medication adherence and risk of cardiovascular disease among older adults: a population-based cohort study. J Am Heart Assoc. 2017;6(6):e006056. | spa |
dc.relation.references | Katholi RE, Rocha-Singh KJ. The role of renal sympathetic nerves in hypertension: has percutaneous renal denervation refocused attention on their clinical significance? Prog Cardiovasc Dis. 2009;52(3):243–8. | spa |
dc.relation.references | Esler M, Jennings G, Korner P, Willett I, Dudley F, Hasking G, et al. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension. 1988;11(1):3–20. | spa |
dc.relation.references | Schultz HD, Li YL, Ding Y. Arterial chemoreceptors and sympathetic nerve activity: implications for hypertension and heart failure. Hypertension. 2007;50(1):6–13. | spa |
dc.relation.references | Stella A, Zanchetti A. Functional role of renal afferents. Physiol Rev. 1991;71(3):659–82. | spa |
dc.relation.references | Schiller AM, Haack KK, Pellegrino PR, Curry PL, Zucker IH. Unilateral renal denervation improves autonomic balance in conscious rabbits with chronic heart failure. Am J Physiol Regul Integr Comp Physiol. 2013;305(8):R886–92. | spa |
dc.relation.references | Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension: results in 1,266 cases. J Am Med Assoc. 1953;152(16):1501–4. | spa |
dc.relation.references | Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicenter safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–81. | spa |
dc.relation.references | Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57(5):911–7. | spa |
dc.relation.references | Krum H, Schlaich MP, Sobotka PA, Bohm M, Mahfoud F, Rocha-Singh K, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383(9917):622–9. | spa |
dc.relation.references | Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9. | spa |
dc.relation.references | Esler MD, Böhm M, Sievert H, Rump CL, Schmieder RE, Krum H, et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J. 2014;35(26):1752–9. | spa |
dc.relation.references | Kandzari DE, Bhatt DL, Sobotka PA, O'Neil WW, Esler M, Flack JM, et al. Catheter-based renal denervation for resistant hypertension: Rationale and design of the SYMPLICITY HTN-3 trial. Clin Cardiol. 2012;35(9):528– 35. | spa |
dc.relation.references | Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36(4):219–27. | spa |
dc.relation.references | Kandzari DE, Kario K, Mahfoud F, Cohen SA, Pilcher G, Pocock S, et al. The SPYRAL HTN global clinical trial program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFFMED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. Am Heart J. 2016;171(1):82–91. | spa |
dc.relation.references | Osborn JW, Banek CT. Catheter-based renal nerve ablation as a novel hypertension therapy: lost, and then found, in translation. Hypertension. 2018;71(3):383–8. | spa |
dc.relation.references | Böhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444–51. | spa |
dc.relation.references | Mahfoud F, Böhm M, Azizi M, Pathak, Zaleski ID, Ewen S, et al. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J. 2015;36(33):2219–27. | spa |
dc.rights | LUIS ANDRES DULCEY SARMIENTO, Jhon Fredy Castillo Blanco, Juan Sebastian Theran Leon, Raimondo Caltagirone Miceli - 2025 | spa |
dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
dc.rights.coar | http://purl.org/coar/access_right/c_abf2 | spa |
dc.rights.creativecommons | Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0. | spa |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0 | spa |
dc.source | https://revistas.juanncorpas.edu.co/index.php/cuarzo/article/view/640 | spa |
dc.subject | Hypertension | eng |
dc.subject | Treatment | eng |
dc.subject | Therapy | eng |
dc.subject | Drugs | eng |
dc.subject | Hipertensión | spa |
dc.subject | Tratamiento, | spa |
dc.subject | Terapia | spa |
dc.subject | Fármacos | spa |
dc.title | Eficacia de la Denervación simpática renal como ultimo escalafón terapéutico en hipertensión refractaria, revisión de la literatura. | spa |
dc.title.translated | Efficacy of renal sympathetic denervation as the last therapeutic echelon in refractory hypertension, literature review | eng |
dc.type | Artículo de revista | spa |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | spa |
dc.type.coar | http://purl.org/coar/resource_type/c_dcae04bc | spa |
dc.type.coarversion | http://purl.org/coar/version/c_970fb48d4fbd8a85 | spa |
dc.type.content | Text | spa |
dc.type.driver | info:eu-repo/semantics/article | spa |
dc.type.local | Journal article | eng |
dc.type.redcol | http://purl.org/redcol/resource_type/ARTREV | spa |
dc.type.version | info:eu-repo/semantics/publishedVersion | spa |
dspace.entity.type | Publication | spa |